首页 正文

Best practice & research. Clinical rheumatology. 2009 Aug;23(4):539-47. doi: 10.1016/j.berh.2008.12.007

Malignancy in systemic lupus erythematosus: what have we learned?

系统性红斑狼疮恶变的研究进展与思考 翻译改进

Sasha Bernatsky  1, Rosalind Ramsey-Goldman, Ann E Clarke

作者单位 +展开

作者单位

  • 1 Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, Quebec, Canada. sasha.bernatsky@mail.mcgill.ca
  • DOI: 10.1016/j.berh.2008.12.007 PMID: 19591783

    摘要 Ai翻译

    What have we learnt about cancer risk in systemic lupus erythematosus (SLE) over the past decade? One important lesson is that data do confirm a slightly increased risk in SLE for all cancers combined, compared to that in the general population. However, it is clear that this is largely driven by an increased risk for haematological malignancies, particularly non-Hodgkin's lymphoma (NHL), although Hodgkin's lymphoma may be increased as well. In addition, t... ...点击完成人机验证后继续浏览
    Copyright © Best practice & research. Clinical rheumatology. 中文内容为AI机器翻译,仅供参考!

    相关内容

    全文链接
    引文链接
    复制
    已复制!
    推荐内容
    Malignancy in systemic lupus erythematosus: what have we learned?